Therefore, MET-targeting tyrosine kinase inhibitors (MET-TKI) have been used in the treatment of various cancers, including non-small cell lung cancer (NSCLC), metastatic medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma, with acceptable therapeutic outcomes; multiple advanced clinical trials are currently underway [11,12]. This evidence concerns the gene MET and hereditary clear cell renal cell carcinoma.